Core Viewpoint - Enwei Pharmaceutical Co., Ltd. held its seventh meeting of the third board of directors on August 25, 2025, where several important resolutions were passed, indicating the company's commitment to transparency and compliance with regulations [1][2][3]. Summary by Relevant Sections Meeting Details - The meeting was conducted both in-person and via communication, with all 8 directors present, and was chaired by Chairman Xue Yongjiang, complying with the Company Law and Articles of Association [1]. Resolutions Passed - The 2025 Semi-Annual Report and its summary were approved, confirming that the report adheres to accounting standards and accurately reflects the company's operational status for the first half of 2025, with a unanimous vote of 8 in favor [2]. - A special report on the storage and use of raised funds was approved, indicating that the company has complied with regulations regarding the management of these funds, also receiving a unanimous vote of 8 in favor [2]. - The proposal for the extension of certain fundraising investment projects was approved, deemed a prudent decision aligned with the company's long-term development strategy, again with a unanimous vote of 8 in favor [2]. Future Implications - The resolutions from this meeting are expected to significantly impact the future development of Enwei Pharmaceutical, prompting investors to closely monitor the company's subsequent activities [3].
恩威医药第三届董事会第七次会议：通过半年报、募资报告及项目延期议案